Aclaris Therapeutics(GB:0H8T)
$3.92-0.22 (-5.31%)
GB:0H8T
Aclaris Therapeutics financials statements
$3.92
At close:-0.22 (-5.31%)
Aclaris Therapeutics (0H8T) Ratios
0 Followers
Aclaris Therapeutics Ratios
GB:0H8T's free cash flow for Q3 2026 was $-24.09M. For the 2026 fiscal year, GB:0H8T's free cash flow was decreased by $-13.00K and operating cash flow was $-24.08M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.28 | 3.99 | 4.16 | 10.55 | 8.94 |
| Quick Ratio | 5.28 | 3.99 | 4.16 | 10.55 | 8.94 |
| Cash Ratio | 0.70 | 0.78 | 1.29 | 2.06 | 1.19 |
| Solvency Ratio | -1.12 | -2.03 | -2.18 | -1.51 | -1.67 |
| Operating Cash Flow Ratio | -1.64 | -0.64 | -2.53 | -3.08 | -2.27 |
| Short-Term Operating Cash Flow Coverage | -85.50 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 93.98M | $ 61.18M | $ 88.63M | $ 174.57M | $ 151.16M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.56 | 1.42 | 1.26 | 1.29 | 1.27 |
| Debt Service Coverage Ratio | -117.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.02 | 0.00 | 0.01 | 0.01 | 0.01 |
| Net Debt to EBITDA | 0.28 | 0.48 | 0.34 | 0.53 | 0.41 |
| Profitability Margins | |||||
| Gross Profit Margin | 73.28% | 85.09% | 42.14% | 59.80% | 30.29% |
| EBIT Margin | -829.58% | -280.59% | -372.22% | -286.21% | -967.08% |
| EBITDA Margin | -823.78% | -276.28% | -369.46% | -283.53% | -953.42% |
| Operating Profit Margin | -975.91% | -758.18% | -311.55% | -302.01% | -1327.07% |
| Pretax Profit Margin | -829.58% | -705.48% | -284.32% | -292.11% | -1343.96% |
| Net Profit Margin | -829.58% | -705.48% | -283.15% | -292.11% | -1343.96% |
| Continuous Operations Profit Margin | -829.58% | -705.48% | -283.15% | -292.11% | -1343.96% |
| Net Income Per EBT | 100.00% | 100.00% | 99.59% | 100.00% | 100.00% |
| EBT Per EBIT | 85.01% | 93.05% | 91.26% | 96.72% | 101.27% |
| Return on Assets (ROA) | -40.46% | -59.94% | -44.82% | -34.14% | -36.17% |
| Return on Equity (ROE) | -62.98% | -84.90% | -56.29% | -43.98% | -46.04% |
| Return on Capital Employed (ROCE) | -57.94% | -75.20% | -58.49% | -38.62% | -39.30% |
| Return on Invested Capital (ROIC) | -57.70% | -75.20% | -58.10% | -38.51% | -39.18% |
| Return on Tangible Assets | -40.46% | -59.94% | -44.88% | -35.10% | -37.21% |
| Earnings Yield | -17.58% | -68.89% | -120.71% | -8.46% | -11.02% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.41 | 58.87 | 104.86 | 61.47 | 10.85 |
| Payables Turnover | 0.16 | 0.60 | 2.04 | 1.16 | 0.47 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 18.57 | 19.29 | 27.07 | 5.06 |
| Asset Turnover | 0.05 | 0.08 | 0.16 | 0.12 | 0.03 |
| Working Capital Turnover Ratio | 0.07 | 0.19 | 0.20 | 0.15 | 0.06 |
| Cash Conversion Cycle | -2037.28 | -606.93 | -175.74 | -309.96 | -739.66 |
| Days of Sales Outstanding | 259.55 | 6.20 | 3.48 | 5.94 | 33.63 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 2296.83 | 613.13 | 179.22 | 315.90 | 773.29 |
| Operating Cycle | 259.55 | 6.20 | 3.48 | 5.94 | 33.63 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.38 | -0.26 | -1.12 | -1.04 | -0.92 |
| Free Cash Flow Per Share | -0.38 | -0.26 | -1.14 | -1.05 | -0.92 |
| Dividend Paid and CapEx Coverage Ratio | -424.44 | -165.91 | -59.84 | -111.68 | -169.27 |
| Capital Expenditure Coverage Ratio | -424.44 | -165.91 | -59.84 | -111.68 | -169.27 |
| Operating Cash Flow Coverage Ratio | -22.27 | 0.00 | -183.86 | -98.78 | -75.23 |
| Operating Cash Flow to Sales Ratio | -6.02 | -1.07 | -2.51 | -2.27 | -7.71 |
| Free Cash Flow Yield | -12.79% | -10.54% | -108.64% | -6.64% | -6.36% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -5.68 | -1.45 | -0.83 | -11.82 | -9.08 |
| Price-to-Sales (P/S) Ratio | 47.18 | 10.24 | 2.35 | 34.52 | 122.00 |
| Price-to-Book (P/B) Ratio | 3.58 | 1.23 | 0.47 | 5.20 | 4.18 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -7.82 | -9.49 | -0.92 | -15.07 | -15.73 |
| Price-to-Operating Cash Flow Ratio | -7.84 | -9.55 | -0.94 | -15.20 | -15.82 |
| Price-to-Earnings Growth (PEG) Ratio | 0.08 | -0.04 | 0.18 | 0.70 | -0.27 |
| Enterprise Value Multiple | -5.45 | -3.23 | -0.29 | -11.65 | -12.38 |
| Enterprise Value | 351.38M | 167.13M | 33.85M | 982.53M | 798.21M |
| EV to EBITDA | -5.45 | -3.23 | -0.29 | -11.65 | -12.38 |
| EV to Sales | 44.90 | 8.93 | 1.08 | 33.02 | 118.06 |
| EV to Free Cash Flow | -7.44 | -8.28 | -0.43 | -14.41 | -15.22 |
| EV to Operating Cash Flow | -7.46 | -8.33 | -0.43 | -14.54 | -15.31 |
| Tangible Book Value Per Share | 0.84 | 2.01 | 2.25 | 2.92 | 3.35 |
| Shareholders’ Equity Per Share | 0.84 | 2.01 | 2.25 | 3.03 | 3.48 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.06 | 0.24 | 0.45 | 0.46 | 0.12 |
| Net Income Per Share | -0.53 | -1.71 | -1.27 | -1.33 | -1.60 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 2.51 | 0.76 | 1.02 | 1.39 |
| Research & Development to Revenue | 6.73 | 1.79 | 3.15 | 2.62 | 6.48 |
| SG&A to Revenue | 2.81 | 1.19 | 1.00 | 0.84 | 3.49 |
| Stock-Based Compensation to Revenue | 1.58 | 0.58 | 0.66 | 0.51 | 2.08 |
| Income Quality | 0.73 | 0.15 | 0.89 | 0.78 | 0.57 |
Currency in USD
